MXPA02009777A - Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer. - Google Patents
Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer.Info
- Publication number
- MXPA02009777A MXPA02009777A MXPA02009777A MXPA02009777A MXPA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A
- Authority
- MX
- Mexico
- Prior art keywords
- dose
- day
- galantamine
- treatment
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02009777A true MXPA02009777A (es) | 2003-03-27 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02009777A MXPA02009777A (es) | 2000-04-03 | 2001-03-28 | Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (hu) |
| JP (1) | JP2003528913A (hu) |
| KR (1) | KR20020086911A (hu) |
| CN (1) | CN1430514A (hu) |
| AU (2) | AU2001265844B2 (hu) |
| BG (1) | BG107093A (hu) |
| BR (1) | BR0109770A (hu) |
| CA (1) | CA2310926C (hu) |
| CZ (1) | CZ20023543A3 (hu) |
| EE (1) | EE200200554A (hu) |
| HR (1) | HRP20020778A2 (hu) |
| HU (1) | HUP0300566A3 (hu) |
| IL (1) | IL152061A0 (hu) |
| MX (1) | MXPA02009777A (hu) |
| NO (1) | NO20024746L (hu) |
| PL (1) | PL361272A1 (hu) |
| RU (1) | RU2002129298A (hu) |
| SK (1) | SK15422002A3 (hu) |
| WO (1) | WO2001074339A2 (hu) |
| ZA (1) | ZA200207935B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| AU2004262897B9 (en) | 2003-07-25 | 2009-12-17 | F. Hoffmann-La Roche Ag | Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| MX344177B (es) | 2008-03-27 | 2016-12-08 | Chase Pharmaceuticals Corp | Uso y composicion para tratar la demencia. |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| CN107847504A (zh) * | 2015-05-18 | 2018-03-27 | 斯奈普泰克发展有限责任公司 | 淀粉状蛋白β的加兰他敏清除 |
| WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| WO2000030446A1 (en) | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| SI1140105T1 (en) * | 1998-12-24 | 2004-04-30 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20020778A2 (en) | 2004-04-30 |
| CA2310926A1 (en) | 2000-10-04 |
| NO20024746L (no) | 2002-11-28 |
| HUP0300566A2 (hu) | 2003-06-28 |
| AU2001265844B2 (en) | 2005-04-14 |
| WO2001074339A2 (en) | 2001-10-11 |
| SK15422002A3 (sk) | 2003-04-01 |
| BG107093A (bg) | 2003-06-30 |
| ZA200207935B (en) | 2004-01-30 |
| IL152061A0 (en) | 2003-05-29 |
| AU6584401A (en) | 2001-10-15 |
| RU2002129298A (ru) | 2004-03-27 |
| JP2003528913A (ja) | 2003-09-30 |
| BR0109770A (pt) | 2003-02-04 |
| HUP0300566A3 (en) | 2004-10-28 |
| CN1430514A (zh) | 2003-07-16 |
| EP1272192A2 (en) | 2003-01-08 |
| CZ20023543A3 (cs) | 2003-03-12 |
| CA2310926C (en) | 2002-10-15 |
| WO2001074339A3 (en) | 2002-09-12 |
| EE200200554A (et) | 2004-04-15 |
| PL361272A1 (en) | 2004-10-04 |
| KR20020086911A (ko) | 2002-11-20 |
| NO20024746D0 (no) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6334511B2 (ja) | 新規方法 | |
| Brown | Ibogaine in the treatment of substance dependence | |
| Sival et al. | Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial | |
| Dumitrascu et al. | Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series | |
| Crow et al. | The coincidence of schizophrenia and Parkinsonism: some neurochemical implications | |
| CA2310950C (en) | An efficacious dosage regiment of galantamine that reduces side effects | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| US20220184074A1 (en) | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor | |
| MXPA02009777A (es) | Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer. | |
| JPH0920666A (ja) | 成熟遅延および類似疾患の治療用医薬組成物 | |
| AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| CN115427037A (zh) | 达立克生(daridorexant)的医药用途 | |
| US20120010242A1 (en) | Low dose pipamperone in treating mood disorders | |
| US12023315B2 (en) | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | |
| US20060172993A1 (en) | Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease | |
| Haimov | Melatonin rhythm abnormalities and sleep disorders in the elderly | |
| Yeo et al. | Oral agents for the management of agitation and agitated delirium in critically ill patients | |
| Sramek et al. | A bridging study of LU 25-109 in patients with probable Alzheimer's disease | |
| De Wilde et al. | A double‐blind randomized placebo‐controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression | |
| AU2017324942B2 (en) | Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-Tau and improve cognition | |
| JP2002517448A (ja) | 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用 | |
| US11752141B2 (en) | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | |
| WO2021055576A1 (en) | Combination of modafinil and an ampakine for improving cognition | |
| TW202302109A (zh) | 認知損傷之治療 | |
| Pitt et al. | A Review of the Use of Donepezil in the Treatment of Alzheimer’s Disease |